Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BR115 for Injection in Patients With Advanced Solid Malignancies

NCT06388902 is registered in ClinicalTrials.gov with BioRay Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06388902
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06388902 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Clinical Study of the Safety, Tolerability and Efficacy of BR115 for Injection in Patients With Advanced Solid Malignancies
Lead sponsor
BioRay Pharmaceutical Co., Ltd.
Phase
Phase 1
Overall status
Suspended
Start date
February 19, 2024
Completion date
December 31, 2028
Enrollment
120 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid malignancies